Ebos Group Ltd (ASX: EBO) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Ebos Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Ebos Group Ltd (ASX: EBO)
Latest News
Healthcare Shares
3 ASX 200 healthcare shares to buy with 35% to 103% upside ahead
Superannuation
How much superannuation do I need to earn $90,000 per year in passive income?
ASX Share Market News
ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus
Dividend Investing
16 ASX 200 shares with ex-dividend dates next week
Healthcare Shares
EBOS FY26 earnings: profit edges higher, dividend steady
Dividend Investing
These ASX 200 shares could generate $10,000 per year in passive income
Value Investing
Down 50% – Are these the best value ASX 200 shares right now?
Broker Notes
4 ASX shares Macquarie says could return more than 40%
Broker Notes
Macquarie names 2 ASX shares that could jump more than 80%
Dividend Investing
These 3 ASX shares will deliver better than 5% dividend yields, Macquarie says
Broker Notes
Why did this broker just lower its outlook on this ASX 200 stock?
Healthcare Shares
EBOS Group trims FY26 earnings guidance as fuel costs bite
Frequently Asked Questions
-
Yes, EBOS Group has historically paid two partially franked shareholder dividends a year.
-
EBOS Group generally pays its shareholder dividends in March and September.
-
Yes, EBOS has a dividend reinvestment plan to allow shareholders to reinvest all or part of their dividends.
-
EBOS Group Ltd listed on the ASX on 6 September 2013.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 27 Aug 2026 | $0.0217 | 0.00% | Supplemental | 18 Sep 2026 |
| 05 Mar 2026 | $0.0251 | 0.00% | Supplemental | 27 Mar 2026 |
| 04 Sep 2025 | $0.6150 | 0.00% | Final | 24 Sep 2025 |
| 27 Feb 2025 | $0.0251 | 0.00% | Supplemental | 21 Mar 2025 |
| 29 Aug 2024 | $0.5043 | 0.00% | Final | 18 Sep 2024 |
| 29 Feb 2024 | $0.1510 | 0.00% | Supplemental | 22 Mar 2024 |
| 07 Sep 2023 | $0.0251 | 0.00% | Supplemental | 29 Sep 2023 |
| 07 Sep 2023 | $0.4705 | 0.00% | Final | 29 Sep 2023 |
| 02 Mar 2023 | $0.0234 | 0.00% | Supplemental | 17 Mar 2023 |
| 02 Mar 2023 | $0.4259 | 0.00% | Interim | 17 Mar 2023 |
| 08 Sep 2022 | $0.0216 | 0.00% | Supplemental | 30 Sep 2022 |
| 08 Sep 2022 | $0.3800 | 0.00% | Final | 30 Sep 2022 |
| 03 Mar 2022 | $0.0207 | 0.00% | Supplemental | 18 Mar 2022 |
| 03 Mar 2022 | $0.3917 | 0.00% | Interim | 18 Mar 2022 |
| 09 Sep 2021 | $0.0203 | 0.00% | Supplemental | 24 Sep 2021 |
| 09 Sep 2021 | $0.3953 | 0.00% | Final | 24 Sep 2021 |
| 04 Mar 2021 | $0.0188 | 0.00% | Supplemental | 18 Mar 2021 |
| 04 Mar 2021 | $0.3506 | 0.00% | Interim | 18 Mar 2021 |
| 24 Sep 2020 | $0.0176 | 0.00% | Supplemental | 09 Oct 2020 |
| 24 Sep 2020 | $0.3289 | 0.00% | Final | 09 Oct 2020 |
| 12 Mar 2020 | $0.0165 | 0.00% | Supplemental | 03 Apr 2020 |
| 12 Mar 2020 | $0.3232 | 0.00% | Interim | 03 Apr 2020 |
| 26 Sep 2019 | $0.0163 | 0.00% | Supplemental | 11 Oct 2019 |
| 26 Sep 2019 | $0.3076 | 0.00% | Final | 11 Oct 2019 |
| 14 Mar 2019 | $0.0152 | 0.00% | Supplemental | 05 Apr 2019 |
| 14 Mar 2019 | $0.2920 | 0.00% | Interim | 05 Apr 2019 |
| 27 Sep 2018 | $0.2871 | 0.00% | Final | 12 Oct 2018 |
| 15 Mar 2018 | $0.0146 | 0.00% | Supplemental | 06 Apr 2018 |
| 15 Mar 2018 | $0.2766 | 0.00% | Interim | 06 Apr 2018 |
| 28 Sep 2017 | $0.0146 | 0.00% | Supplemental | 13 Oct 2017 |
| 28 Sep 2017 | $0.2664 | 0.00% | Final | 13 Oct 2017 |
| 16 Mar 2017 | $0.2453 | 0.00% | Interim | 07 Apr 2017 |
| 29 Sep 2016 | $0.2697 | 0.00% | Final | 14 Oct 2016 |
| 10 Mar 2016 | $0.2075 | 0.00% | Interim | 01 Apr 2016 |
| 30 Sep 2015 | $0.2024 | 0.00% | Final | 16 Oct 2015 |
| 11 Mar 2015 | $0.1884 | 0.00% | Interim | 02 Apr 2015 |
| 01 Oct 2014 | $0.1650 | 0.00% | Final | 17 Oct 2014 |
| 12 Mar 2014 | $0.1776 | 0.00% | Interim | 04 Apr 2014 |
| 06 Apr 2011 | $0.1350 | 0.00% | Interim | 21 Apr 2011 |
| 08 Sep 2010 | $0.1750 | 0.00% | Final | 08 Oct 2010 |
| 15 Mar 2010 | $0.1350 | 0.00% | Interim | 13 Apr 2010 |
| 07 Sep 2009 | $0.1450 | 0.00% | Final | 02 Oct 2009 |
| 23 Mar 2009 | $0.1050 | 0.00% | Interim | 21 Apr 2009 |
| 15 Sep 2008 | $0.0238 | 0.00% | Supplemental | 10 Oct 2008 |
| 15 Sep 2008 | $0.1350 | 0.00% | Final | 10 Oct 2008 |
| 14 Apr 2008 | $0.0168 | 0.00% | Supplemental | 09 May 2008 |
| 14 Apr 2008 | $0.0950 | 0.00% | Interim | 09 May 2008 |
| 23 Oct 2007 | $0.0229 | 0.00% | Supplemental | 26 Oct 2007 |
| 23 Oct 2007 | $0.1300 | 0.00% | Final | 26 Oct 2007 |
| 16 Apr 2007 | $0.0168 | 0.00% | Supplemental | 20 Apr 2007 |
| 16 Apr 2007 | $0.0950 | 0.00% | Interim | 20 Apr 2007 |
| 24 Oct 2006 | $0.0229 | 0.00% | Supplemental | 27 Oct 2006 |
| 24 Oct 2006 | $0.1300 | 0.00% | Final | 27 Oct 2006 |
| 03 Apr 2006 | $0.0168 | 0.00% | Supplemental | 07 Apr 2006 |
| 03 Apr 2006 | $0.0950 | 0.00% | Interim | 07 Apr 2006 |
| 03 Oct 2005 | $0.0221 | 0.00% | Supplemental | 07 Oct 2005 |
| 03 Oct 2005 | $0.1250 | 0.00% | Final | 07 Oct 2005 |
| 14 Mar 2005 | $0.0159 | 0.00% | Supplemental | 18 Mar 2005 |
| 14 Mar 2005 | $0.0900 | 0.00% | Interim | 18 Mar 2005 |
EBO ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Ebos Group Ltd
EBOS Group Ltd (ASX: EBO) is the largest pharmaceutical wholesaler and distributor across Australia, New Zealand, and Southeast Asia. The company provides pharmaceutical and wellness products to community pharmacies, public and private hospitals, day surgeries, general practices, aged care facilities, and specialist clinics.
EBOS Group also operates an animal health product wholesale, manufacturing, and retail business, as well as providing third-party logistics services.
The vast majority of the company's revenue derives from its services to community pharmacies and institutional healthcare providers, which accounts for about 80% of revenue. Its Australian operations similarly contribute around 80% of its total revenue.
EBO Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 03 Nov 2026 | $17.27 | $0.23 | 1.35% | 97,239 | $17.50 | $17.50 | $16.89 |
| 02 Nov 2026 | $17.04 | $0.43 | 2.59% | 255,150 | $16.75 | $17.07 | $16.49 |
| 30 Oct 2026 | $16.61 | $0.52 | 3.23% | 207,514 | $16.21 | $16.75 | $16.10 |
| 29 Oct 2026 | $16.09 | $-0.04 | -0.25% | 66,248 | $16.25 | $16.25 | $15.92 |
| 28 Oct 2026 | $16.13 | $-0.41 | -2.48% | 66,832 | $16.67 | $16.67 | $16.12 |
| 27 Oct 2026 | $16.54 | $-0.47 | -2.76% | 114,956 | $16.90 | $16.90 | $16.47 |
| 26 Oct 2026 | $17.01 | $0.26 | 1.55% | 147,795 | $16.90 | $17.09 | $16.72 |
| 23 Oct 2026 | $16.75 | $-0.41 | -2.39% | 126,718 | $17.64 | $17.64 | $16.69 |
| 22 Oct 2026 | $17.16 | $0.08 | 0.47% | 174,975 | $17.11 | $17.35 | $16.97 |
| 21 Oct 2026 | $17.08 | $0.82 | 5.04% | 124,844 | $16.56 | $17.25 | $16.56 |
| 20 Oct 2026 | $16.26 | $0.02 | 0.12% | 67,163 | $16.01 | $16.32 | $16.01 |
| 19 Oct 2026 | $16.24 | $-0.35 | -2.11% | 84,131 | $16.50 | $16.60 | $16.13 |
| 16 Oct 2026 | $16.59 | $0.15 | 0.91% | 106,509 | $16.44 | $16.69 | $16.39 |
| 15 Oct 2026 | $16.44 | $0.53 | 3.33% | 137,725 | $16.20 | $16.46 | $15.84 |
| 14 Oct 2026 | $15.91 | $0.02 | 0.13% | 46,454 | $15.82 | $16.02 | $15.82 |
| 13 Oct 2026 | $15.89 | $-0.06 | -0.38% | 69,904 | $16.10 | $16.10 | $15.69 |
| 12 Oct 2026 | $15.95 | $0.65 | 4.25% | 80,487 | $15.49 | $16.00 | $15.49 |
| 09 Oct 2026 | $15.30 | $0.08 | 0.53% | 71,125 | $15.22 | $15.35 | $15.16 |
| 08 Oct 2026 | $15.22 | $0.02 | 0.13% | 105,388 | $15.20 | $15.35 | $15.08 |
| 07 Oct 2026 | $15.20 | $-0.15 | -0.98% | 50,498 | $15.50 | $15.50 | $15.20 |
| 06 Oct 2026 | $15.35 | $0.39 | 2.61% | 76,866 | $14.98 | $15.50 | $14.98 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 18 Sep 2026 | Stuart McLauchlan | Issued | 160 | $3,275 |
Dividend Reinvestment Plan (DRP). NZ$
|
| 18 Sep 2026 | Julie Tay | Issued | 85 | $897 |
Dividend Reinvestment Plan (DRP).
|
| 18 Sep 2026 | Coline McConville | Issued | 27 | $448 |
Dividend Reinvestment Plan (DRP).
|
| 31 Aug 2026 | Matthew Muscio | Expiry | 17,859 | $310,925 |
As advised by the company. 17,859 rights lapsed
|
| 27 Mar 2026 | Stuart McLauchlan | Issued | 134 | $2,960 |
Dividend Reinvestment Plan (DRP). NZ$
|
| 27 Mar 2026 | Julie Tay | Issued | 71 | $825 |
Dividend Reinvestment Plan (DRP).
|
| 27 Mar 2026 | Coline McConville | Issued | 22 | $485 |
Dividend Reinvestment Plan (DRP). NZ$
|
| 27 Feb 2026 | Stuart McLauchlan | Buy | 1,500 | $36,054 |
On-market trade. NZ$
|
| 05 Dec 2025 | Coline McConville | Buy | 1,000 | $24,347 |
On-market trade.
|
| 27 Nov 2025 | Julie Tay | Buy | 1,000 | $28,000 |
On-market trade. NZ$
|
| 10 Nov 2025 | Matthew Muscio | Buy | 3,800 | $108,563 |
On-market trade. NZ$
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Elizabeth(Liz) Mary Coutts | Non-Executive DirectorNon-Executive Chairman | Nov 2013 |
Ms Coutts is Chair of the Remuneration Committee and a member of the Audit and Risk Committee. She is Chair of Oceania Healthcare Limited and 2degrees Group Limited, and Director of EBOS Group subsidiaries in New Zealand. She is a former Chair of Skellerup Holdings Limited, Ports of Auckland Limited, Meritec Group, Industrial Research, Life Pharmacy Limited, former director of Air New Zealand Limited, the Health Funding Authority, Sanford Limited, the Yellow Group of Companies and Tennis Auckland Region Incorporated, former Deputy Chairman of Public Trust, former board member of Sport NZ, former member of the Pharmaceutical Management Agency (Pharmac) and Marsh New Zealand Advisory Board, former Commissioner for both the Commerce and Earthquake Commissions, former external monetary policy adviser to the Governor of the Reserve Bank of New Zealand, a former president of the Institute of Directors Inc and former Chief Executive of the Caxton Group of Companies.
|
| Mr Mark Alan Bloom | Non-Executive Director | Sep 2022 |
Mr Bloom is a member of the Audit and Risk Committee. He is a non-executive director of ASX listed Storage King and AGL Energy Limited and a director of JewishCare NSW. He is a former director of Pacific Smiles Group Limited and Abacus Property Group. Mark has over 35 years experience as a finance executive, including as Chief Financial Officer at ASX listed Scentre Group Limited from its formation in July 2014 through to his retirement in April 2019. Prior to this, he was the Deputy Group CFO of Westfield Group for 11 years. He has also held a number of senior finance roles, including being CFO and executive director for insurance and financial services companies Liberty Life, South Africa and Manulife Financial, Canada.
|
| Mr Stuart McLauchlan | Non-Executive Director | Jul 2019 |
Mr McLauchlan is Chairman of the Audit and Risk Committee and a member of the Remuneration Committee. He is a Chartered Fellow of the Institute of Directors and a Past President. He is a senior partner of GS McLauchlan & Co, and a Fellow of the New Zealand Institute of Chartered Accountants. He is currently chairman of Scott Technology Ltd and ADInstruments Ltd, and a nonexecutive director of Southlink Health Education Trust, Argosy Property Ltd, Dunedin Casinos Ltd and Scenic Hotels Group. He is also a governor of the New Zealand Sports Hall of Fame. He was formerly a member of the Marsh New Zealand Advisory Board, and director of Ngai Tahu Tourism Ltd.
|
| Mr Matthew Peter Muscio | Non-Executive Director | Jan 2025 |
Mr Muscio was previously a board member for the Medical Technology Association of Australia from 2017 to 2023 and currently serves as Chair of Pacific Health Group and as a non executive board member of Tetrous Inc, a regenerative medicine company. His career spans more than 25 years in the medical device industry with the last 15 years in medical technology distribution under both public and private ownership models.
|
| Dr Tracey Leigh Batten | Non-Executive Director | Jul 2021 |
Ms Batten is a member of the Remuneration Committee. She is currently a non executive director of Medibank Private Limited and Nanosonics Limited, and from 1 July 2026 is an independent director of IHH Healthcare Berhad. She was previously Chair of the Accident Compensation Corporation, a non executive director of National Institute of Water and Atmospheric Research, Abano Healthcare Group Limited and various other healthcare related research institutes, charities and industry and government bodies. During her executive career she was Group CEO of Imperial College Healthcare NHS Trust in the United Kingdom, Group CEO of St Vincent s Health Australia, CEO of Eastern Health and CEO of Dental Health Services Victoria.
|
| Ms Julie Tay | Non-Executive Director | May 2023 |
Ms Tay is currently a director of Sonova, a global hearing care solutions company, headquartered in Switzerland and listed on the Swiss stock exchange. She has over 30 years experience in international leadership roles across consumer healthcare, medical devices and digital healthcare. She was most recently Senior Vice President and Managing Director, Asia Pacific and member of the global Executive Management Committee for Align Technology. Prior to this time, she was regional head of Bayer Healthcare (Diabetes Care) in Asia Pacific and also previously held senior executive roles in Asia at Johnson Diversey and Johnson & Johnson. She has also completed the International Directors Program at INSEAD, and is a member of the Young President's Organization (YPO).
|
| Ms Coline McConville | Non-Executive Director | Feb 2025 |
Ms McConville brings to EBOS 20 years of governance experience advising a range of organisations operating in different countries and industries. Her expertise includes advising across acquisitive portfolio companies, complex distribution organisations, capital intensive businesses, consumer driven vertically integrated and global service companies. During her executive career, she was Chief Executive Officer and Chief Operating Officer for Clear Channel Communications (now iHeartMedia Inc.) and a management consultant with McKinsey and Co and LEK Consulting. She is currently a director of 3i Group (private equity) and was a member of the Supervisory Board of German based Tui AG (tourism and travel) until February 2026. Her previous directorships include Kings Cross Central General Partnership, TUI Travel, UTV Media, Travis Perkins, Fevertree Drinks, Inchcape, Wembley National Stadium, Shed Media, Halifax and HBOS.
|
| Grant Viney | CEO Animal Care |
-
|
|
| Kristine James | CEO Medical Technology |
-
|
|
| Nick Munroe | CEO Retail Pharmacy Brands |
-
|
|
| Brett Barons | CEO Symbion & Healthcare Distribution |
-
|
|
| Adam Hall | Chief Executive Officer |
-
|
|
| Alistair Gray | Chief Financial Officer |
-
|
|
| Mithran Naiker | Chief Information Officer |
-
|
|
| Jacinta McCarthy | Executive General Manager |
-
|
|
| Janelle Cain | General Counsel |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| BNP Paribas Nominees (NZ) Limited NZCSD | 22,368,532 | 10.81% |
| JP Morgan Nominees Australia Limited | 15,940,350 | 7.70% |
| Custodial Services Limited | 15,325,872 | 7.41% |
| HSBC Nominees (New Zealand) Limited NZCSD | 14,447,604 | 6.98% |
| Accident Compensation Corporation NZCSD | 11,057,913 | 5.34% |
| Forsyth Barr Custodians Limited | 10,902,317 | 5.27% |
| Sybos Holdings Pte Limited | 9,957,825 | 4.81% |
| Apex Custodian Nominees (NZ) Limited NZCSD | 8,994,618 | 4.35% |
| Citibank Nominees (New Zealand) Limited NZCSD | 7,822,492 | 3.78% |
| HSBC Nominees A/C NZ Superannuation Fund Nominees Limited NZCSD | 7,788,795 | 3.76% |
| HSBC Nominees (New Zealand) Limited A/C State Street NZCSD | 7,227,463 | 3.49% |
| JPMorgan Chase Bank NA NZ Branch Segregated Clients Acct NZCSD | 7,193,425 | 3.48% |
| HSBC Custody Nominees (Australia) Limited | 4,805,567 | 2.32% |
| FNZ Custodians Limited | 4,613,901 | 2.23% |
| JBWere (NZ) Nominees Limited | 3,366,313 | 1.63% |
| New Zealand Depository Nominee Limited | 3,353,232 | 1.62% |
| Citicorp Nominees Pty Limited | 2,584,580 | 1.25% |
| Generate Kiwisaver Public Trust Nominees Limited NZCSD | 2,461,561 | 1.19% |
| Simplicity Nominees Limited NNZCSD | 2,387,814 | 1.15% |
| PT (Booster Investments) Nominees Limited | 1,928,218 | 0.93% |